Following the COVID-19 pandemic, mRNA-based vaccines have been shown to provide rapid and precise immune responses, however, this technology has much wider applications.
Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver
AstraZeneca has joined the ranks of big pharma companies bolting on RNA-based technology platforms in the wake of the stellar success of mRNA vaccines for COVID-19.
Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.